Reuters logo
Eli Lilly profit drops sharply on Zyprexa generics
January 31, 2012 / 11:56 AM / 6 years ago

Eli Lilly profit drops sharply on Zyprexa generics

(Reuters) - Eli Lilly & Co’s (LLY.N) quarterly profit dropped 27 percent after its top-selling Zyprexa schizophrenia treatment lost U.S. patent protection and saw competition from generic rivals.

The drugmaker backed its 2012 outlook that calls for a steep drop in profit this year due largely to the Zyprexa loss. It said an independent safety committee recommended continuing two late-stage clinical trials for its closely watched experimental Alzheimer’s treatment.

Lilly’s fourth-quarter net income fell to $858.2 million, or 77 cents per share, from $1.17 billion, or $1.05 per share, a year ago.

Excluding items, earnings of 87 cents per share were 6 cents ahead of the average estimate of analysts, according to Thomson Reuters I/B/E/S.

Reporting by Lewis Krauskopf and Ransdell Pierson; Editing by Derek Caney

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below